Lupin receives approval from US FDA for Turqoz
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
This product would be manufactured at Lupin's Nagpur facility in India
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
Subscribe To Our Newsletter & Stay Updated